Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Interest Expenses (2022 - 2026)

MoonLake Immunotherapeutics' Interest Expenses history spans 3 years, with the latest figure at $2.3 million for Q1 2026.

  • Quarterly Interest Expenses rose 12505.56% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Mar 2026, up 52666.67% year-over-year, with the annual reading at $7.2 million for FY2025, N/A changed from the prior year.
  • Interest Expenses came in at $2.3 million for Q1 2026, up from $2.0 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.2 million in Q3 2025 to a low of $657.0 in Q1 2022.
  • The 3-year median for Interest Expenses is $2.0 million (2025), against an average of $1.6 million.
  • The largest YoY upside for Interest Expenses was 12505.56% in 2026 against a maximum downside of 12505.56% in 2026.
  • MoonLake Immunotherapeutics' Interest Expenses stood at $657.0 in 2022, then soared by 303400.76% to $2.0 million in 2025, then rose by 13.79% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Interest Expenses are $2.3 million (Q1 2026), $2.0 million (Q4 2025), and $3.2 million (Q3 2025).